PMC Lee, E., Park, H.-Y., Kim, S.-W
15ChalasaniN, FontanaRJ, BonkovskyHL,
Analytes (M-CuP or D-CuP) were diluted in PBST buffer (10 mM phosphate-buffered saline, 0.05% Tween-20, pH 7.4) and injected at increasing concentrations at a flow rate of 30 L/min, with 120 s association and 180 s dissociation phases
For cagrilintide specifically, the coming years will determine whether its distinct mechanism can carve out a meaningful roleeither as a standalone therapy through the RENEW program or as part of combination approaches like CagriSema and potentially future pairings Other questions about cagrilintide Because cagrilintide is still in clinical development, many common questions relate to its availability, safety, and how it compares with existing medications
Kekessie I, Wegner K, Martinez I, Kopach ME, White TD, Tom JK, et al